

Determination of the Quality of Life Instrument that is most preferred by patients with thyroid cancer

Submission date 10/08/2011	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 26/09/2011	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 30/04/2018	Condition category Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

<http://cancerhelp.cancerresearchuk.org/trials/a-trial-to-see-which-qol-questionnaire-people-with-thyroid-cancer-find-most-helpful-deteqt>

Contact information

Type(s)

Scientific

Contact name

Mr Mathew Kivell

Contact details

University Hospitals Coventry and Warwickshire NHS Trust
Clifford Bridge Road
Coventry
United Kingdom
CV2 2DX

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

10323

Study information

Scientific Title

Determination of which Health Related Quality of Life (HRQoL) instrument is most preferred by patients with early and advanced thyroid cancer

Acronym

DeteQT

Study objectives

To determine which Health Related Quality of Life (HRQoL) instruments patients with early and advanced thyroid cancer find most helpful in facilitating communication of their health problems to their clinicians.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The Black Country Research Ethics Committee, 18th March 2011, ref: 11/WM/0051

Study design

Phase III, randomised, observational, qualitative trial

Primary study design

Observational

Secondary study design

Randomised controlled trial

Study setting(s)

GP practice

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Head and neck cancer

Interventions

Patients are randomised to receive study instruments in varying order of presentation. There are no treatment arms or drugs used as it is a quality of life questionnaire study. The patients will be approached in the clinic where the trial will be explained to them and if they are interested, they will sign the consent form and take the questionnaire to complete and send back to us.

Intervention Type

Other

Phase

Phase III

Primary outcome measure

Patient preference: identification of preferred quality of life instrument

The study only comprises of one questionnaire pack (as explained above). This includes four different quality of life questionnaires that the patient will complete and then answer a set of evaluation questions at the end. Once we receive them back, they are entered on a spreadsheet and then sent to a statistician

Secondary outcome measures

No secondary outcome measures

Overall study start date

28/07/2011

Completion date

12/07/2013

Eligibility

Key inclusion criteria

1. Patients 18 years old or over
 2. Patients attending the thyroid or head neck cancer clinic who are:
 - 2.1. Being treated or undergoing follow-up for differentiated (papillary or follicular) thyroid cancer or
 - 2.2. Being investigated or treated for differentiated (papillary or follicular) thyroid cancer recurrence
- Note: patients with high grade variants such as insular carcinoma or poorly differentiated carcinoma are eligible
3. Male or female

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

Planned Sample Size: 466; UK Sample Size: 466

Key exclusion criteria

1. Patients who do not sufficiently understand the English language and those with learning disabilities as these are standardized and validated questionnaires which are in English
2. Patients who have medullary thyroid cancer or anaplastic thyroid cancer or lymphoma of the thyroid
3. Patients having a diagnostic hemithyroidectomy for possible thyroid cancer

Date of first enrolment

28/07/2011

Date of final enrolment

12/07/2013

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

University Hospitals Coventry and Warwickshire NHS Trust

Coventry

United Kingdom

CV2 2DX

Sponsor information

Organisation

University Hospitals Coventry & Warwickshire NHS Trust (UK)

Sponsor details

Medical Oncology

Clinical Sciences Research Unit

Clinical Sciences Building

Clifford Bridge Road

Coventry

England

United Kingdom

CV2 2DX

Sponsor type

Hospital/treatment centre

Website

<http://www.uhcv.nhs.uk/>

ROR

<https://ror.org/025n38288>

Funder(s)

Funder type

Charity

Funder Name

Macmillan Cancer Support (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration